The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).
Daniel Costin Danila
Research Funding - Genentech
Russell Zelig Szmulewitz
No relevant relationships to disclose
Celestia S. Higano
Research Funding - Genentech
Houston Gilbert
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Robert S. Kahn
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Katie Wood
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Priya Agarwal
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Kedan Lin
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Omar Kabbarah
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Bernard M. Fine
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Daniel J. Maslyar
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Ulka N. Vaishampayan
Consultant or Advisory Role - Dendreon; Janssen Oncology; Novartis; Pfizer
Research Funding - Genentech/Roche; Novartis
Other Remuneration - Dendreon (Speakers Bureau); Genentech/Roche; Janssen Biotech (Speakers Bureau); Medivation (Speakers Bureau); Novartis (Speakers Bureau); Pfizer (Educational Presentation Development); Pfizer (Speakers Bureau)